← Back to Search

Care to Plan for Alzheimer's Disease

N/A
Waitlist Available
Led By Joseph E Gaugler, PhD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Inclusion Criteria: The care recipient has received a provider diagnosis of Alzheimer's disease or a related dementia (ADRD); and 2) the caregiver is 21 years of age or older; 3) English-speaking; 4) self-identifies as someone who provides help to the person with ADRD because of their cognitive impairments; 5) the caregiver indicates a willingness to use Care to Plan (CtP); and 6) caregiver resides in one of 4 Riverside Health regions (based on zip code).
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up phase ii baseline, 3-month, 6-month
Awards & highlights

Study Summary

Care to Plan: a Tailored Resource for Family Members of Persons With Dementia

Eligible Conditions
  • Alzheimer's Disease
  • Dementia
  • Memory Loss

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~phase ii baseline, 3-month, 6-month
This trial's timeline: 3 weeks for screening, Varies for treatment, and phase ii baseline, 3-month, 6-month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Caregiver Self-efficacy
Secondary outcome measures
Care to Plan Service Use
Caregiver Distress: Role Captivity
Center for Epidemiological Studies Depression (CES-D)
+2 more
Other outcome measures
Acceptability and Feasibility

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Phase II [Randomized]: TreatmentExperimental Treatment1 Intervention
Participants randomized to this treatment arm will receive the Care to Plan (CtP) intervention as a part of Phase II.
Group II: Phase I [Non-randomized]: TreatmentExperimental Treatment1 Intervention
Participants enrolled in Phase I of the project to receive the intervention [non-randomized; no comparison group].
Group III: Phase II [Randomized]: ControlActive Control1 Intervention
Participants randomized to a usual care control group as a part of Phase II. Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Care to Plan
2019
N/A
~70

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,381 Previous Clinical Trials
1,588,710 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,675 Previous Clinical Trials
28,020,860 Total Patients Enrolled
Joseph E Gaugler, PhDPrincipal InvestigatorUniversity of Minnestoa

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Care to Plan: a Tailored Resource for Family Members of Persons With Dementia
2019. "Care to Plan: a Tailored Resource for Family Members of Persons With Dementia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03901456.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top